Laura J. Esserman, MD, MBA, discusses the rationale and design for the phase 2 I-SPY2 trial.
Laura J. Esserman, MD, MBA
Advertisement
Articles by Laura J. Esserman, MD, MBA
Laura J. Esserman, MD, MBA, professor, University of California, San Francisco Helen Diller Comprehensive Cancer Center, 2018 Giant of Cancer Care® for Cancer Diagnostics, discusses the elements of the I-SPY 2 trial in breast cancer.
Laura J. Esserman, MD, MBA, professor, University of California, San Francisco Helen Diller Comprehensive Cancer Center, 2018 Giant of Cancer Care® for Cancer Diagnostics, discusses the I-SPY 2 trial in breast cancer.
Advertisement
Latest Updated Articles
Dr. Esserman Discusses the I-SPY 2 Trial in Breast CancerOctober 8th 2018
Dr. Esserman on the Elements of the I-SPY 2 Trial in Breast CancerJanuary 29th 2019
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
2
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
3
Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026
4
HERTHENA-Breast04 Is Set to Delineate the Role of HER3-Targeted Therapy in Advanced HR+ Breast Cancer
5